Signal / field note
Peptide news: reading the next offer
A field note for comparing an announcement with a provider, pharmacy and proposed preparation.
Read the federal step
The federal news is an interim section 503A enforcement approach while the bulk-substance list goes through rulemaking. The notice addresses state-licensed pharmacies, federal facilities and licensed physicians. It does not announce a permanent listing or section 503B permission. Compounded products remain unapproved. HHS can revisit the approach if safety or product-quality concerns emerge.
Public inspection noticeThe Federal Register record was still unpublished when checked on October 29, 2026. October 30 was the scheduled publication date. The notice describes a draft that binds neither HHS nor the public; a scheduled publication should not be read as an established effective date.
Public inspection noticeFor a reader comparing services, the next useful step is to look at the proposed preparation. Work through the form and route below before turning to the company announcement. That order keeps the federal document and the advertised service in view without treating them as the same evidence.
Match the preparation
Conditional discretion ends at each peptide’s final inclusion/exclusion rule.
HHS policyForms and routes
All conditions apply.
Scroll horizontally to read both columns.
| Form | Routes |
|---|---|
| BPC-157 acetate | Oral, topical, subcutaneous, intramuscular; excludes intravenous |
| TB-500 acetate (thymosin beta-4 fragment) | Intramuscular or subcutaneous injection |
| Epitalon acetate | Intramuscular or subcutaneous injection, in intermittent courses |
| Semax free base | Intranasal |
| KPV acetate | Topical or oral |
| MOTS-c acetate | Intramuscular or subcutaneous injection |
Read every condition
- Appendix A listing.
- Appendix B identity: amino-acid sequence, chemical structure, molecular weight and formula; listed routes.
- Section-510-registered facility; valid certificate of analysis (COA), Appendix B characterization/tests.
- Original bulk maker: section 510 registration, CGMP/FD&C compliance, physical location on COA; registered intermediaries document manufacturer/COA validation.
- FDA and compounding/destination states receive product, serious-adverse-event and quality reports; events regardless of causality; MedWatch for events/quality; labels explain reporting. Product details: ingredient, strength per unit, original maker, facility identifier, form, route.
- Label: “This is a compounded drug product. Not for resale.”
- One active ingredient from Appendix A.
- Oral products: document adequate human oral bioavailability of the supplied formulation.
- Only FDA-510(k)-cleared syringes as co-packaged or drug-containing delivery devices; noninjectable interpretation unresolved.
- FD&C compliance, sanitary preparation, patient-specific prescriptions.
Identify the pharmacy
Compounded products are not FDA-approved. FDA does not assess their safety, effectiveness or quality before marketing. Poor compounding can cause contamination or incorrect strength.
Compounding questions and answersRoutine oversight of state-licensed pharmacies outside 503B generally falls to state boards; FDA also inspects. Registered 503B outsourcing facilities are primarily FDA-supervised.
Compounding questions and answersFinished preparations meeting 503A conditions are exempt from current good manufacturing practice (CGMP); 503B products are subject to those standards.
Compounding questions and answersFind out which pharmacy will compound the prescription, then use its legal identity to verify the relevant state license.
Compounding questions and answersRead the company preview
Hims & Hers used its October 29 announcement to preview Peptides+ and collect names for a future launch. Its planned menu names sermorelin, glutathione, B12, NAD+ and L-carnitine, followed by BPC-157 and TB-500 only when allowable. These are therapies; they are not all peptides.
Peptides+ announcementThe company also describes independent prescribers, pharmacy supply and ongoing support as parts of its intended service. Its forward-looking statement qualifies the launch, timing, availability and manufacturing plans. We have not tested a checkout, a prescription, delivery, state eligibility or a formulation.
Peptides+ announcementThe Peptides+ preview does not establish the current offerings of the Hims or Hers GLP-1 program.
Peptides+ announcementReader questions
Does the scheduled date settle the next step?
No. Publication status needs a fresh check. The notice allows comments for two weeks after publication, so a calendar deadline should follow the actual published record rather than the date shown in advance.
Public inspection noticeWhat does joining the list establish?
It establishes interest in an announced service, not a confirmed prescription or shipment. Revisit the specific offer when the company publishes one.
Peptides+ announcementWhat should I discuss with my clinician?
Ask whether an approved medicine can meet your needs and why compounding is being proposed for you.
Compounding questions and answersAbout this field note
This is a document comparison for readers evaluating a service. We have left the earlier peptide reference and provider review in their original clinical and historical scope. The dated links alongside those pages point here for this separate policy discussion; they do not revise the earlier evidence ratings or price research.
AI assisted the drafting and source comparison. This article has no clinician review. We read extracted primary-source text; we did not visually inspect the PDF’s chemical drawings or independently assess its underlying studies. We have not verified a pharmacy’s compliance, state access or an individual treatment. This field note gives no dosing or treatment recommendation.
Sources
- HHS policyHHSChecked
- Public inspection noticeFederal RegisterChecked
- Peptides+ announcementHims & HersChecked
- Compounding questions and answersFDAChecked